- Home
- EDIT vs ACIU Comparison
EDIT vs ACIU Comparison
Compare EDIT & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- ACIU
- Stock Information
- Founded
- EDIT 2013
- ACIU 2003
- Country
- EDIT United States
- ACIU Switzerland
- Employees
- EDIT N/A
- ACIU N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- EDIT Health Care
- ACIU Health Care
- Exchange
- EDIT Nasdaq
- ACIU Nasdaq
- Market Cap
- EDIT 263.7M
- ACIU 213.3M
- IPO Year
- EDIT 2016
- ACIU 2016
- Fundamental
- Price
- EDIT $2.57
- ACIU $2.04
- Analyst Decision
- EDIT Buy
- ACIU Strong Buy
- Analyst Count
- EDIT 12
- ACIU 1
- Target Price
- EDIT $5.40
- ACIU $12.00
- AVG Volume (30 Days)
- EDIT 1.7M
- ACIU 109.7K
- Earning Date
- EDIT 08-12-2025
- ACIU 08-05-2025
- Dividend Yield
- EDIT N/A
- ACIU N/A
- EPS Growth
- EDIT N/A
- ACIU N/A
- EPS
- EDIT N/A
- ACIU N/A
- Revenue
- EDIT $38,901,000.00
- ACIU $36,362,036.00
- Revenue This Year
- EDIT N/A
- ACIU N/A
- Revenue Next Year
- EDIT N/A
- ACIU $1,022.98
- P/E Ratio
- EDIT N/A
- ACIU N/A
- Revenue Growth
- EDIT N/A
- ACIU 86.71
- 52 Week Low
- EDIT $0.91
- ACIU $1.43
- 52 Week High
- EDIT $4.12
- ACIU $3.98
- Technical
- Relative Strength Index (RSI)
- EDIT 46.57
- ACIU 44.83
- Support Level
- EDIT $2.66
- ACIU $2.05
- Resistance Level
- EDIT $2.78
- ACIU $2.19
- Average True Range (ATR)
- EDIT 0.22
- ACIU 0.11
- MACD
- EDIT -0.02
- ACIU -0.01
- Stochastic Oscillator
- EDIT 39.39
- ACIU 4.55
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.